Solarea Bio

Solarea Bio is a biotech company that develops microbial therapeutics aimed to treat indications derived from chronic inflammation to aid human health.

It specializes in the research and development of therapeutics that are derived from natural sources and are aimed to treat indications derived from chronic inflammation, enabling hospitals to provide medicinal drugs for improved quality of life. The company generates a large database of the complete genomic sequences of microbes derived from healthy foods. Using computational approaches, Solarea generates synergistic combinations of bacteria, fungi, and prebiotic fibers with powerful anti-inflammatory capabilities to address specific chronic conditions that afflict large numbers of people. These have been validated in-vitro and in-vivo in preclinical mouse models. Its first application aims to aid in the dietary management of the metabolic processes that cause osteopenia and osteoporosis in postmenopausal women. This provides a nature-based solution to improving women’s health and well-being.

The Cambridge, Massachusetts-based company was established in 2017 by Eric Schott, Gerardo Toledo, and Jillian DeWalt.

Solarea Bio headquartered in United States, North America, operates in the Biotechnology, Health Care, Wellness, Therapeutics sector. The company focuses on Biotechnology and has secured $1.7B in funding across 64 round(s). With a team of 11-50 employees, Solarea Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - Solarea Bio, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.